齐齐哈尔医学院学报
齊齊哈爾醫學院學報
제제합이의학원학보
JOURNAL OF QIQIHAR MEDICAL COLLEGE
2015年
8期
1106-1108
,共3页
体腔内灌注%白细胞介素-2%顺铂%恶性胸腹腔积液%疗效
體腔內灌註%白細胞介素-2%順鉑%噁性胸腹腔積液%療效
체강내관주%백세포개소-2%순박%악성흉복강적액%료효
Body cavity perfusion%Interleukin-2%Cisplatin%Malignant pleural effusion%Efficacy
目的：探讨体腔内灌注白介素2联合顺铂治疗恶性胸腹腔积液临床疗效。方法将兴宁市中医院收治的恶性胸腔积液60例患者随机分为观察组与对照组，每组各30例，对照组于胸（腹）腔内灌注顺铂40 mg／m2治疗；观察组采用体腔内灌注白介素-2100万U＋顺铂40 mg／m2治疗，连续治疗3周，比较两组患者的临床疗效、KPS评分、肿瘤标志物水平及不良反应。结果实验组完全缓解（CR）19例，部分缓解（PR）7例，病情稳定（SD）3例，进展（PD）1例；对照组CR 8例，PR 15例，SD 4例，PD 3例，实验组疗效显著优于对照组，P＝0．010，实验组治疗后的CEA 水平显著低于对照组（271．2±104．9μg／mlvs 318．3±134．9μg／ml），实验组治疗后的KPS评分（59．3±2．8分vs 55．7±3．6分）显著高于对照组，P＜0．001；两组患者的血液毒性、胃肠道不良反应、发热、胸痛及腹痛发生率比较无统计学差异，P＞0．05。结论体腔内灌注白介素2联合顺铂治疗恶性胸腹腔积液具有更好的疗效，可显著降低CEA水平，提升KPS评分，且不明显增加不良反应发生率。
目的：探討體腔內灌註白介素2聯閤順鉑治療噁性胸腹腔積液臨床療效。方法將興寧市中醫院收治的噁性胸腔積液60例患者隨機分為觀察組與對照組，每組各30例，對照組于胸（腹）腔內灌註順鉑40 mg／m2治療；觀察組採用體腔內灌註白介素-2100萬U＋順鉑40 mg／m2治療，連續治療3週，比較兩組患者的臨床療效、KPS評分、腫瘤標誌物水平及不良反應。結果實驗組完全緩解（CR）19例，部分緩解（PR）7例，病情穩定（SD）3例，進展（PD）1例；對照組CR 8例，PR 15例，SD 4例，PD 3例，實驗組療效顯著優于對照組，P＝0．010，實驗組治療後的CEA 水平顯著低于對照組（271．2±104．9μg／mlvs 318．3±134．9μg／ml），實驗組治療後的KPS評分（59．3±2．8分vs 55．7±3．6分）顯著高于對照組，P＜0．001；兩組患者的血液毒性、胃腸道不良反應、髮熱、胸痛及腹痛髮生率比較無統計學差異，P＞0．05。結論體腔內灌註白介素2聯閤順鉑治療噁性胸腹腔積液具有更好的療效，可顯著降低CEA水平，提升KPS評分，且不明顯增加不良反應髮生率。
목적：탐토체강내관주백개소2연합순박치료악성흉복강적액림상료효。방법장흥저시중의원수치적악성흉강적액60례환자수궤분위관찰조여대조조，매조각30례，대조조우흉（복）강내관주순박40 mg／m2치료；관찰조채용체강내관주백개소-2100만U＋순박40 mg／m2치료，련속치료3주，비교량조환자적림상료효、KPS평분、종류표지물수평급불량반응。결과실험조완전완해（CR）19례，부분완해（PR）7례，병정은정（SD）3례，진전（PD）1례；대조조CR 8례，PR 15례，SD 4례，PD 3례，실험조료효현저우우대조조，P＝0．010，실험조치료후적CEA 수평현저저우대조조（271．2±104．9μg／mlvs 318．3±134．9μg／ml），실험조치료후적KPS평분（59．3±2．8분vs 55．7±3．6분）현저고우대조조，P＜0．001；량조환자적혈액독성、위장도불량반응、발열、흉통급복통발생솔비교무통계학차이，P＞0．05。결론체강내관주백개소2연합순박치료악성흉복강적액구유경호적료효，가현저강저CEA수평，제승KPS평분，차불명현증가불량반응발생솔。
Objective To explore the clinical efficacy of body cavity perfusion of interleukin-2 in combination with cisplatin treat for malignant pleural effusions.Methods 60 patients with malignant pleural effusions from January 2014 to February 2015 were randomly divided into the experimental group and the control group.The control group were Primed 40mg /m2 cisplatin in the chest (abdominal) cavity,and the experimental group were Primed 40mg /m2 cisplatin combined interleukin-2(1 million u)in the chest (abdominal) cavity.the treatment were continuous 3 weeks.The Clinical efficacy, KPS score, tumor marker levels and adverse reactions were compared.Results The complete remission ( CR) 19 cases, partial remwassion ( PR) 7 cases of stable Disease ( SD) 3 cases PRogress ( PD) 1 cases in the experimental group,and that was CR 8 cases, PR 15 cases, SD 4 cases, PD3 cases in the control group.The efficacy in the experimental group was significantly better than the control group, P=0.010.The CEA levels in the experimental group after treatment was significantly lower than the control group (271.2 ±104.9μg/ml vs 318.3 ±134.9μg/ml).The KPS score (59.3 ±2.8 minutes vs 55.7 ±3.6 min) in the experimental group was significantly higher than the control group, P<0.001.The incidence of Hematologic toxicity, gastrointestinal adverse reactions, fever, chest pain and abdominal pain in the two groups compared with no significant difference, P>0.05.Conclusions Body cavity perfusion of interleukin-2 in combination with cisplatin treat for malignant pleural effusions with better efficacy, it could significantly reduce CEA level and enhance KPS score, and it didn't increase the incidence of adverse reactions.
